Positive Phase 1 Data for Subcutaneous BRIUMVI in Myasthenia Gravis; TG Therapeutics Initiates Registration-Directed Phase 2 Trial
TGTX sits 66% above its 52-week low of $25.28.
Summary
TG Therapeutics announced positive topline Phase 1 data for its subcutaneous BRIUMVI in Myasthenia Gravis (MG) patients, with 82% achieving a clinically meaningful improvement. The company is now initiating a potential registration-directed Phase 2 trial for this new indication. This development significantly expands the potential market for BRIUMVI, which is already approved for Multiple Sclerosis. It builds on recent positive news, including strong Q1 results and successful Phase 3 data for BRIUMVI in MS. The progress of this new Phase 2 trial will be a key focus for future growth.
At the time of this announcement, TGTX was trading at $42.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $25.28 to $44.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.